PT  - JOURNAL ARTICLE
AU  - TAMARI, KEISUKE
AU  - ISOHASHI, FUMIAKI
AU  - AKINO, YUICHI
AU  - SUZUKI, OSAMU
AU  - SEO, YUJI
AU  - YOSHIOKA, YASUO
AU  - HAYASHI, YOSHITO
AU  - NISHIDA, TSUTOMU
AU  - TAKEHARA, TETSUO
AU  - MORI, MASAKI
AU  - DOKI, YUICHIRO
AU  - OGAWA, KAZUHIKO
TI  - Risk Factors for Pericardial Effusion in Patients with Stage I Esophageal Cancer Treated with Chemoradiotherapy
DP  - 2014 Dec 01
TA  - Anticancer Research
PG  - 7389--7393
VI  - 34
IP  - 12
4099  - http://ar.iiarjournals.org/content/34/12/7389.short
4100  - http://ar.iiarjournals.org/content/34/12/7389.full
SO  - Anticancer Res2014 Dec 01; 34
AB  - Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥41.6%, age ≥66 years, body mass index (BMI) ≥19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.